Original paper
CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Abstract
Purpose: Malignant mesothelioma (MM) is an aggressive cancer, resistant to current therapies. Membrane chondroitin sulphate proteoglycan 4 (CSPG4), which has been successfully targeted in melanoma and breast cancer, was found highly expressed in MM, but not in normal mesothelium. Therefore, we explored CSPG4 as a suitable target for monoclonal antibody (mAb)–based immunotherapy for MM. Experimental design: We assayed adhesion, motility,...
Paper Details
Title
CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Published Date
Sep 30, 2012
Journal
Volume
18
Issue
19
Pages
5352 - 5363
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History